{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Td+%28tetanus+toxoid%29",
    "query": {
      "intervention": "Td (tetanus toxoid)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 33,
    "total_pages": 4,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Td+%28tetanus+toxoid%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-26T02:54:44.802Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06639607",
      "title": "PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Midline Glioma",
        "Diffuse Midline High-grade Glioma",
        "Medulloblastoma",
        "Ependymoma"
      ],
      "interventions": [
        {
          "name": "PEP-CMV vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus booster",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "4 Years to 25 Years"
      },
      "enrollment_count": 68,
      "start_date": "2026-09-30",
      "completion_date": "2051-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-26T02:54:44.802Z",
      "location_count": 3,
      "location_summary": "St Louis, Missouri • Durham, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06639607"
    },
    {
      "nct_id": "NCT02097849",
      "title": "Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Relapsing Forms of Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "dimethyl fumarate",
          "type": "DRUG"
        },
        {
          "name": "tetanus diphtheria toxoids vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "23-valent pneumococcal polysaccharide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "non-pegylated interferon",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 71,
      "start_date": "2015-02-28",
      "completion_date": "2016-05-02",
      "has_results": true,
      "last_update_posted_date": "2017-06-02",
      "last_synced_at": "2026-09-26T02:54:44.802Z",
      "location_count": 14,
      "location_summary": "Gilbert, Arizona • Thornton, Colorado • Fort Lauderdale, Florida + 11 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Thornton",
          "state": "Colorado"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02097849"
    },
    {
      "nct_id": "NCT00109330",
      "title": "A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diphtheria",
        "Tetanus",
        "Acellular Pertussis"
      ],
      "interventions": [
        {
          "name": "Combined diphtheria, tetanus, acellular pertussis vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "10 Years to 18 Years"
      },
      "enrollment_count": 4116,
      "start_date": "2002-11",
      "completion_date": "2004-04",
      "has_results": false,
      "last_update_posted_date": "2016-09-09",
      "last_synced_at": "2026-09-26T02:54:44.802Z",
      "location_count": 44,
      "location_summary": "Mesa, Arizona • Tempe, Arizona • Jonesboro, Arkansas + 39 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Escondido",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00109330"
    },
    {
      "nct_id": "NCT00536120",
      "title": "The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "BG00002 (natalizumab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "keyhole limpet hemocyanin (KLH)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "tetanus diphtheria toxoid vaccine (Td)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2008-01",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2017-02-15",
      "last_synced_at": "2026-09-26T02:54:44.802Z",
      "location_count": 10,
      "location_summary": "Fullerton, California • Centennial, Colorado • Farmington Hills, Michigan + 7 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        },
        {
          "city": "Patchogue",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00536120"
    },
    {
      "nct_id": "NCT05096481",
      "title": "PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Grade Glioma",
        "Diffuse Intrinsic Pontine Glioma",
        "Recurrent Medulloblastoma"
      ],
      "interventions": [
        {
          "name": "PEP-CMV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Tetanus Diphtheria Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "3 Years to 39 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-07-18",
      "completion_date": "2030-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-26T02:54:44.802Z",
      "location_count": 13,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05096481"
    },
    {
      "nct_id": "NCT03063736",
      "title": "Entolimod, an Adjuvant for Vaccine Augmentation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Substance Use Disorders"
      ],
      "interventions": [
        {
          "name": "Entolimod",
          "type": "DRUG"
        },
        {
          "name": "Td Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "MALE",
        "summary": "18 Years to 40 Years · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2017-12-08",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-09-01",
      "last_synced_at": "2026-09-26T02:54:44.802Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03063736"
    },
    {
      "nct_id": "NCT05294588",
      "title": "Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gonorrhea Male"
      ],
      "interventions": [
        {
          "name": "Cefixime",
          "type": "DRUG"
        },
        {
          "name": "Ceftriaxone",
          "type": "DRUG"
        },
        {
          "name": "Ciprofloxacin",
          "type": "DRUG"
        },
        {
          "name": "Neisseria gonorrhoeae strain FA1090",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Meningococcal Group B Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus-diptheria Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "MALE",
        "summary": "18 Years to 35 Years · Male only"
      },
      "enrollment_count": 65,
      "start_date": "2022-04-18",
      "completion_date": "2026-02-05",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-09-26T02:54:44.802Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05294588"
    },
    {
      "nct_id": "NCT06254326",
      "title": "ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Oligodendroglioma",
        "Progressive Oligodendroglioma"
      ],
      "interventions": [
        {
          "name": "TTRNA-DC vaccines with GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Hematopoietic Stem cells (HSCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TTRNA-xALT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td vaccine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 12,
      "start_date": "2024-09-19",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-09-26T02:54:44.802Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06254326"
    },
    {
      "nct_id": "NCT02864368",
      "title": "Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "5-day TMZ",
          "type": "DRUG"
        },
        {
          "name": "21-day TMZ",
          "type": "DRUG"
        },
        {
          "name": "PEP-CMV: Component A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Tetanus-Diphtheria booster",
          "type": "DRUG"
        },
        {
          "name": "Tetanus Pre-Conditioning",
          "type": "DRUG"
        },
        {
          "name": "PEP-CMV: Component B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Eric Thompson, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2016-12-07",
      "completion_date": "2020-06-15",
      "has_results": true,
      "last_update_posted_date": "2022-06-09",
      "last_synced_at": "2026-09-26T02:54:44.802Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02864368"
    },
    {
      "nct_id": "NCT03927222",
      "title": "Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Tetanus-Diphtheria Toxoid (Td)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "111-Indium-labeling of Cells for in vivo Trafficking Studies",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2019-09-30",
      "completion_date": "2023-02-10",
      "has_results": true,
      "last_update_posted_date": "2024-04-08",
      "last_synced_at": "2026-09-26T02:54:44.802Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03927222"
    }
  ]
}